Edwards Lifesciences Corp
NYSE:EW

Watchlist Manager
Edwards Lifesciences Corp Logo
Edwards Lifesciences Corp
NYSE:EW
Watchlist
Price: 75.38 USD 0.76%
Market Cap: 44.5B USD
Have any thoughts about
Edwards Lifesciences Corp?
Write Note

Edwards Lifesciences Corp
Total Liabilities & Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Edwards Lifesciences Corp
Total Liabilities & Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities & Equity CAGR 3Y CAGR 5Y CAGR 10Y
Edwards Lifesciences Corp
NYSE:EW
Total Liabilities & Equity
$13B
CAGR 3-Years
17%
CAGR 5-Years
17%
CAGR 10-Years
14%
Becton Dickinson and Co
NYSE:BDX
Total Liabilities & Equity
$57.3B
CAGR 3-Years
2%
CAGR 5-Years
2%
CAGR 10-Years
16%
Boston Scientific Corp
NYSE:BSX
Total Liabilities & Equity
$38.1B
CAGR 3-Years
6%
CAGR 5-Years
7%
CAGR 10-Years
9%
Stryker Corp
NYSE:SYK
Total Liabilities & Equity
$43.8B
CAGR 3-Years
9%
CAGR 5-Years
10%
CAGR 10-Years
10%
Abbott Laboratories
NYSE:ABT
Total Liabilities & Equity
$74.4B
CAGR 3-Years
0%
CAGR 5-Years
2%
CAGR 10-Years
6%
Intuitive Surgical Inc
NASDAQ:ISRG
Total Liabilities & Equity
$17.7B
CAGR 3-Years
11%
CAGR 5-Years
14%
CAGR 10-Years
17%
No Stocks Found

Edwards Lifesciences Corp
Glance View

Market Cap
44.5B USD
Industry
Health Care
Economic Moat
None

Nestled at the intersection of medical innovation and patient care, Edwards Lifesciences Corp. has long been a pioneer in the field of heart disease solutions. Emerging from its origins in the 1950s, the company has consistently focused on advancing heart valve technology, a critical area given the prevalence and severity of cardiovascular diseases. Their journey began with the development of the first artificial heart valve, setting a foundation of innovation that continues to propel the company forward. Today, Edwards is renowned for its leadership in transcatheter aortic valve replacement (TAVR) technology, an area that revolutionizes the treatment of aortic stenosis, a condition that narrows heart valves and impedes blood flow. This shift from open-heart surgeries to less invasive procedures, facilitated by Edwards' products, has marked a significant turning point in patient care, minimizing recovery times and enhancing patient outcomes. Financially, Edwards Lifesciences thrives on a robust business model centered around its technologically advanced heart valve systems and critical care technologies. The company operates through a direct sales force as well as strategic partnerships, ensuring their devices reach hospitals and healthcare providers globally. Their commitment to research and development ensures a steady pipeline of innovative products, which not only differentiates them in the market but also drives their profitability. Revenue streams are primarily fueled by the sales of their TAVR systems, surgical heart valves, and monitoring technologies—each designed to meet the complex and evolving needs of patients with structural heart diseases. By continually investing in cutting-edge technology and expanding their global reach, Edwards Lifesciences not only supports its bottom line but also positions itself as a leader in the transformative field of medical device innovation.

EW Intrinsic Value
55.54 USD
Overvaluation 26%
Intrinsic Value
Price

See Also

What is Edwards Lifesciences Corp's Total Liabilities & Equity?
Total Liabilities & Equity
13B USD

Based on the financial report for Sep 30, 2024, Edwards Lifesciences Corp's Total Liabilities & Equity amounts to 13B USD.

What is Edwards Lifesciences Corp's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 10Y
14%

Over the last year, the Total Liabilities & Equity growth was 38%. The average annual Total Liabilities & Equity growth rates for Edwards Lifesciences Corp have been 17% over the past three years , 17% over the past five years , and 14% over the past ten years .

Back to Top